Compare Tidewater Inc (TDW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tidewater Inc vs 10X Genomics Inc — how do they compare? Tidewater Inc trades at $85.19 (market cap $4.21B), while 10X Genomics Inc trades at $82.4 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 2.4× Tidewater Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tidewater Inc for 26 Days and 10X Genomics Inc for 92 Days on average.
| TDW | TXG | |
|---|---|---|
Market Cap | $4.21B | $10.07B |
Volume | 590,005 | 5,657,286 |
Sector | Energy | Health |
52-Week High | $100.61 | $97.74 |
52-Week Low | $47.29 | $11.48 |
Typical Hold Time | 26 Days | 92 Days |
Enterprise Value | $4.25B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tidewater (TDW) trades at $85.16, up 2.11% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with an 18.34% net margin and 19.49% ROE, though recent earnings missed expectations in Q1 and Q2 2026. The company completed the Wilson Sons Ultratug acquisition in August 2026, enhancing its offshore services footprint. Cash flow remains robust with $252.54M net cash flow in 2025.
Outlook is mixed: analyst consensus targets $105.50 (23.9% upside), but earnings volatility and competitive pressures pose risks. Institutional interest is strong, with BlackRock investing $503.20M in Q2 2026. Investors should weigh solid fundamentals against execution risks in a volatile energy market.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
